TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from ConvaTec ( (GB:CTEC) ).
ConvaTec Group PLC announced the purchase of 806,991 of its ordinary shares as part of a share buyback program valued up to $300 million. This move, executed through UBS AG London Branch, reflects the company’s strategy to manage its capital structure and potentially enhance shareholder value, with the purchased shares being held in treasury.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.25 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and solid profitability. Technical analysis indicates a moderate upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products and technologies industry, focusing on providing solutions for advanced wound care, ostomy care, continence and critical care, and infusion devices. The company serves healthcare professionals and patients worldwide, aiming to improve the lives of people with chronic conditions.
Average Trading Volume: 9,406,962
Technical Sentiment Signal: Hold
Current Market Cap: £4.61B
See more data about CTEC stock on TipRanks’ Stock Analysis page.